Valuation: Bellicum Pharmaceuticals, Inc.

Market Cap 1.76M 1.6M 1.48M 1.34M 2.52M 165M 2.62M 17.83M 7.05M 88.98M 6.62M 6.48M 281M P/E 2021
-1.77x
P/E 2022 -0.89x
Enterprise Value -20.07M -18.22M -16.83M -15.19M -28.67M -1.88B -29.77M -203M -80.22M -1.01B -75.31M -73.72M -3.2B EV / Sales 2021
-5.43x
EV / Sales 2022 -10.4x
Free-Float
98.45%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 66 23/02/2024
Chief Executive Officer 57 31/01/2017
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-6.68%-18.17% - - 822K
+1.15%-2.81%+55.79%+71.12% 66.37B
+1.62%-0.69%+10.25%+92.90% 58.86B
+1.18%+1.05%+26.72%+87.74% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
+0.30%-1.35%+83.35%+58.24% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -1.15%-2.29%+35.54%+172.85% 45B
Weighted average by Cap. -0.28%-2.18%+35.31%+147.49%

Financials

2021 2022
Net sales 6.2M 5.63M 5.2M 4.69M 8.85M 579M 9.19M 62.65M 24.78M 313M 23.26M 22.77M 988M 1.5M 1.36M 1.26M 1.13M 2.14M 140M 2.22M 15.16M 6M 75.62M 5.63M 5.51M 239M
Net income -9.7M -8.81M -8.14M -7.34M -13.86M -907M -14.39M -98.07M -38.79M -489M -36.41M -35.65M -1.55B -24.97M -22.67M -20.94M -18.89M -35.67M -2.33B -37.03M -252M -99.81M -1.26B -93.7M -91.72M -3.98B
Net Debt -46.16M -41.9M -38.71M -34.92M -65.92M -4.31B -68.44M -466M -184M -2.33B -173M -170M -7.35B -21.84M -19.82M -18.31M -16.52M -31.19M -2.04B -32.38M -221M -87.28M -1.1B -81.93M -80.21M -3.48B
Logo Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Inc is a United States-based company. The Company operates as a biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer.
Employees
13